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Abstract
Objectives: Treatment-resistant Obsessive-Compulsive Disorder (OCD) pa-
tients are defined as those who undergo adequate trials of first-line therapies 
without achieving a satisfactory response. First line treatments for OCD include 
both serotonin reuptake inhibitors (SRIs) and cognitive behavior therapy (CBT). 
Because of the high number of OCD patients not responding to first-line treat-
ments (40-60%) and considering the even greater prevalence rate of residual 
symptoms and significant impairment shown in patients previously described 
as “clinical responders”, the question of the proper treatment of resistant OCD 
is a clinically meaningful and a practical issue for psychiatrists. Antipsychotic 
augmentation proved to be an effective strategy for resistant OCD. However, 
there are unresolved questions concerning which antipsychotic is effective (or 
more effective) and how antipsychotics should be used in terms of doses and 
duration of treatment. The purpose of this study is to systematically review 
available studies on antipsychotic augmentation for treatment-resistant OCD, 
in order to guide the practical choice.
Materials and methods: We searched on PubMed, Psychnet and Cochrane 
Libraries from inception to January 2016. Articles published in English and 
related to the use of antipsychotics in OCD were considered. We evaluated 
meta-analyses, systematic reviews and randomized controlled trials of adult 
patients with treatment-resistant OCD.
Results: Antipsychotic augmentation is an evidence-based option for treatment-
resistant OCD, with a response rate of approximately 50% within the first 4-to-
6 weeks. Aripiprazole (10-15 mg/day) and risperidone (0.5-2 mg/day) are effec-
tive, olanzapine (10 mg/day) is possibly effective. Haloperidol addition is also a 
viable option, particularly in patients with comorbid tic disorders. Given results 
of studies performed to date quetiapine should be regarded as non-effective. 
Preliminary results from open label studies suggest that antipsychotic augmen-
tation, once effective, should be maintained in order to maintain remission. 
Conclusions: Not all antipsychotics are effective as add-on treatments in resis-
tant OCD. Characteristics of patients and side effects generally associated with 
each different antipsychotic may guide the practical choice. Further research is 
required concerning the comparative effectiveness among antipsychotics, the 
optimal target dose and the ideal duration of antipsychotic addition. In our opinion, 
antipsychotic augmentation in patients who responded to this treatment should 
be maintained in order to prevent relapses. However, clinicians must remember 
patients’ exposure to the common and serious adverse effects associated with 
long-term antipsychotic administration, especially metabolic disturbances. 
Key words: Obsessive-Compulsive Disorder (OCD), antipsychotic, augmenta-
tion, treatment, treatment-resistant OCD
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Introduction 
Obsessive-compulsive disorder (OCD) is a heteroge-
neous psychiatric illness with a lifetime prevalence in 
the general population of approximately 2-3%, mak-
ing it a far more common disorder than previously 
believed  1. The diagnosis is made by the presence 
of recurrent or persistent, upsetting thoughts, im-
ages, or urges, which are experienced as intrusive 
and unwanted (obsessions), and excessive repetitive 
behaviors or mental acts performed in response to 
these obsessions (compulsions) 2.
First line treatments for OCD include both sero-
tonin reuptake inhibitors (SRIs) (citalopram, esci-
talopram, fluoxetine, fluvoxamine, paroxetine, ser-
traline, and clomipramine), and cognitive behavior 
therapy (CBT) –  in the forms of exposure and re-
sponse prevention (ERP) and/or cognitive restruc-
turing  3-11. Both the above-mentioned pharmaco-
logical and psychological approaches have been 
recognized more effective than wait-list, inactive 
psychological treatments or placebo in individual 
randomized controlled trials (RCT) 12-15. The sever-
ity of the disorder (in terms of severity of obsessive-
compulsive symptoms or the severity of the associ-
ated depressive symptomatology) and the age of 
the patient might guide clinicians in the choice of 
the first approach: for an adult patient affected by 
a severe OCD, pharmacotherapy with an SSRI is 
generally considered a correct first-line approach. 
Analyzing the relative efficacy between different 
SRIs, no significant difference could be identified 
between citalopram, fluoxetine, fluvoxamine, par-
oxetine and sertraline, according to a Cochrane 
review depicting 17 RCTs 16. Equally, the SSRI es-
citalopram improved OCD symptoms without any 
significant difference as compared to paroxetine 17. 
Nevertheless, 40-60% of OCD patients do not re-
spond satisfactorily to the initial SRI monotherapy 18-20. 
Additionally, those patients who are defined as “clini-
cal responders” according to stringent response cri-
teria (i.e., typically a greater than 25 or 35% decline in 
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) 
rating) often fail to show later on a complete remis-
sion of their symptoms and/or continue to experience 
significant impairment from their residual symptoms 
in terms of reduced quality of life 21. 
Because of the high number of OCD patients not 
responding to first-line treatments, the question of 
the proper treatment of resistant OCD is a clinically 
meaningful and practical issue for psychiatrists. 
Definition of and practical steps to be implemented 
for treatment-resistant OCD
Patients who undergo adequate trials of first-line ther-
apies without achieving a satisfactory response are 
defined as treatment-resistant OCD patients. Clinical 
response is usually defined as a reduction in the Y-
BOCS score ≥ 35% or ≥ 25% with respect to base-
line 22. More specifically, stages of response to treat-
ment have been recently proposed, according to an 
international expert consensus: treatment response 
is defined as 35% or greater reduction of Y-BOCS 
and Clinical Global Impression (CGI) 1 or 2; partial 
response as greater than 25% but less 35% Y-BOCS 
reduction and CGI at least 3; non response as less 
than 25% Y-BOCS reduction and CGI 4. Furthermore, 
remission is achieved if the person no longer meets 
syndromal criteria for the disorder and has no more 
than minimal symptoms (Y-BOCS ≤ 12) and CGI 1 
or 2 for at least one week; recovery is obtained if the 
person no longer meets syndromal criteria for the 
disorder and has no more than minimal symptoms 
(Y-BOCS ≤ 12) and CGI 1 or 2 for at least one year 23.
Practically, several issues must be considered and 
questions have to be addressed, before confirming a 
condition of treatment-resistance of OCD: 
1. clinicians should correctly make the diagnosis of 
OCD. Particularly, other symptoms should not be 
inappropriately considered as obsessions or com-
pulsions (obsessive-compulsive personality dis-
order; ruminations occurring in major depressive 
disorder or other anxiety disorders; repetitive ste-
reotyped behaviors encountered in psychoses, in 
mental retardation or in organic mental disorders; 
obsessive concerns about body shape or ritual-
ized eating behaviors in eating disorders; patterns 
of behaviors, interests or restricted and repetitive 
activities in autism);
2. clinicians should check that the patient has been 
exposed to an adequate pharmacological trial 
(SRIs) in terms of appropriate doses and for at 
least 12 weeks. Guidelines provide minimum 
target and maximum doses to be used in OCD 
(see for example those of the APA Guidelines, il-
lustrated in Table  I); a meta-analysis confirmed 
that moderate-high dosages are more effective in 
treating OCD and thus should be prescribed be-
fore defining a patient as resistant 24;
3. the potential presence of medical or psychiatric 
comorbidities that could affect treatment response 
should be assessed (e.g., paradigmatic the case 
of OCD comorbid with bipolar disorder, where 
treatment with high doses of SRIs could worsen 
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both bipolar disorder – mixed episodes, rapid cy-
cling, switch – and OCD) 25 26;
4. clinicians may also keep in mind that the first avail-
able strategy could be just waiting for the treatment 
to produce a full response, since some individu-
als who fail to improve after three months of treat-
ment at adequate doses may turn into treatment 
responders after additional months of continued 
treatment. This strategy, however, should be strictly 
reserved to patients who showed at least a partial 
response during the initial months of treatment 27 28;
5. finally, psychoeducational interventions directed 
to the families might help to establish a therapeu-
tic alliance, to provide education about the disor-
der and its treatment, to improve family problem 
solving skills, and to ameliorate compliance to 
drug treatments 29-31. Indeed, the family may have 
a potential role in reinforcing the disorder and re-
ducing patient compliance. Family members tend 
to become emotionally over-involved, neglecting 
their own needs and at the same time perpetuat-
ing the cycle of obsessions and compulsions. On 
the other hand, family members might express 
criticism by voicing expectations that the patient 
“just snaps out of it”. Both attitudes, besides wors-
ening relatives’ quality of life 32 33, contribute to the 
maintenance of patient’s symptoms as well 34.
Antipsychotic augmentation in treatment-resistant OCD
Several therapeutic options are available for treat-
ment resistant OCD; however, only two strategies 
are considered, to date, evidence-based treatments 
for resistant OCD based on placebo-controlled rand-
omized trials: antipsychotic augmentation of SRIs and 
cognitive-behavior therapy addition. This latter option 
proved to be effective in several open-label studies 
(see for an example of its use in a naturalistic setting 
resembling that of a clinical practice the study by Al-
bert et al.) 35 and at least one well-performed controlled 
(stress management training as the inactive/placebo 
psychological treatment arm) randomized trial 36. 
Antipsychotic augmentation of SRIs is an evidence-
based treatment for resistant OCD; its efficacy has been 
confirmed by several randomized, double-blind and 
placebo-controlled trials and by several meta-analyses. 
Atypical antipsychotic medications are approved only 
for the treatment of Schizophrenia, Bipolar Disorder 
and Major Depression under drug-specific circum-
stances. However, their use is rapidly increasing and 
their off-label prescription is, at least partially, respon-
sible for their widespread use 37-41. It has been esti-
mated that, among adults, off-label prescriptions rep-
resent 40 to 75% of all antipsychotic prescriptions 41. 
Antipsychotic drugs are generally recommended as a 
class for several diagnoses including treatment-resist-
ant OCD, although they are not all the same in their 
efficacy, reflecting the differences in pharmacokinetic 
and pharmacodynamic profiles of each drug. In fact, 
there are still some unresolved questions concerning 
which atypical antipsychotic could be more effective 
as an evidence-based treatment for treatment-resist-
ant OCD. Moreover, no advice is provided on how to 
use a specific antipsychotic for this specific disorder, 
in terms of doses and duration of treatment.
The purpose of this paper is to systematically review 
available studies on antipsychotic augmentation for 
treatment-resistant OCD, focusing on efficacy and 
comparative effectiveness (where possible) of antip-
Table I. Doses of serotonin reuptake inhibitors (SRIs) in the treatment of obsessive-compulsive disorder according to 
American Psychiatry Association guidelines (2007) 7.
Compound
SRI
Starting dose  
and incremental dose 
(mg/day)*
Usual 
target dose
(mg/day)
Usual 
maximum dose
(mg/day)
Occasionally prescribed 
maximum dose 
(mg/day)† 
Citalopram 20 40-60 80 120
Clomipramine 25 100-250 250 __ ‡
Escitalopram 10 20 40 60
Fluoxetine 20 40-60 80 120
Fluvoxamine 50 200 300 450
Paroxetine 20 40-60 60 100
Sertraline § 50 200 200 400
* Some patients may need to start at half this dose or less to minimize undesired side effects such as nausea or to accomodate anxiety about tak-
ing medications; † These doses are sometimes used for rapid metabolizers or for patients with no or mild side effects and inadeguate therapeutic 
response after 8 weeks or more at the usual maximum dose; ‡ Combined plasma levels of clomipramine plus desmethylclomipramine 12 hours 
after the dose should be kept below 500 mg/mL to minimize risk of seizures and cardiac conduction delay; § Sertraline, along among the selective 
serotonin reuptake inhibitors, is better absorbed with food.
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Table II. Efficacy of antipsychotic augmentation in treatment-resistant OCD: double-blind, placebo-controlled studies.
Antipsychotic Authors Sample (N) Trial duration (weeks) Dose (mg/die) Mean dose (mg/die)
Minimal length of SRI treatment 
before enrollment in the study
Results 
Aripiprazole Muscatello et al., 2011 66
Sayyah et al., 2012 67
40
39
16
12
15 (fixed-dose)
10 (fixed-dose)
15 (fixed-dose)
10 (fixed-dose)
12
12
Aripiprazole > Placebo
Aripiprazole > Placebo
Haloperidol McDougle et al., 1994 54 34 4 2-10 6.2 ± 3.0 12 Haloperidol > Placebo
Olanzapine Bystritsky et al., 2004 68
Shapira et al., 2004 69
26
44
6
6
5-20
5-10
11.2 ± 6.5
6.1 ± 2.1
12
8
Olanzapine > Placebo
Olanzapine = Plabebo
(patients in both arms improved)
Paliperidone Storch et al., 2013 70 34 8 3-9 4.94 8 Paliperidone = Placebo
(patients in both arms improved)
Quetiapine Atmaca et al., 2002 *57
Denys et al., 2004 58
Carey et al., 2005 59
Fineberg et al., 2005 81
Kordon et al., 2008 60
Diniz et al., 2011 #61
27
40
42
21
40
54
8
8
6
16
12
12
50-200
100-300
25-300
50-400
400-600
50-200
91 ± 41
200
168.8 ± 120.8
215 ± 124
-
142 ± 65
12
8
12
12
12
8
Quetiapine > Placebo
Quetiapine > Placebo
Quetiapine = Placebo
Quetiapine = Placebo
Quetiapine = Placebo
Quetiapine < Placebo
Risperidone McDougle et al., 2000 62
Hollander et al., 2003 63
Erzegovesi et al., 2005 64
Simpson et al., 2013 65
36
16
20
60
6
8
6
8
1-6
0.5-3
0.5 (fixed-dose)
0.25-4
2.2 ± 0.7
2.25 ± 0.86
0.5 (fixed-dose)
1.9 ± 1.1
12
12
12
12
Risperidone > Placebo
Risperidone > Placebo
Risperidone > Placebo
Risperidone > Placebo
* Single-blind, placebo-controlled study; # Double-blind placebo and clomipramine controlled study.
sychotics, in order to provide a guidance for clinicians 
on which antipsychotic (and at which dose) should be 
preferred in resistant OCD.
Materials and methods
We searched on PubMed, Psychnet and Cochrane 
Libraries from inception to January  2016. Articles 
published in English and related to the use of antip-
sychotics in OCD were evaluated. The keyword “an-
tipsychotic” was combined using the boolean AND 
with “obsessive-compulsive disorder”. An additional 
search was performed combining OCD with “ari-
piprazole”, “olanzapine”, “quetiapine”, “paliperidone”, 
“risperidone”, “ziprasidone” via the Boolean AND. Fi-
nally, a manual search for reference lists from articles 
selected in the previous search and for any relevant 
reviews was done. Search results were limited to 
open-label trials and randomized controlled trials of 
adult patients with treatment resistant OCD.
Results
Is antipsychotic augmentation an evidence-based 
treatment for resistant OCD?
The use of antipsychotic addition to SRIs in resistant 
OCD is supported by several randomized, double-
blind, placebo-controlled studies; review and meta-
analytical studies also confirm that augmentation of 
SRIs with antipsychotic drugs can be considered a 
valid treatment option in resistant OCD 42-52.
In summary, the evidence based on the meta-analytic 
calculations suggests an efficacy of this pharmacologi-
cal strategy measured by both the response rates (cri-
terion: Y-BOCS reduction ≥ 35%) and the changes in 
Y-BOCS total score; Dold et al. calculated an overall re-
sponse rate to antipsychotic addition (all RCTs, includ-
ing those where antipsychotics proved to be ineffective) 
of approximately 30% 52; however, studies in which the 
active compound (antipsychotic) differentiated from 
placebo (positive studies) found response rates around 
50% 43. When response to antipsychotic addition oc-
curs, it is evident within the first 4-6 weeks  43 50. Ac-
cording to these results, it may be advisable to change 
strategy when antipsychotic addition after 6 weeks re-
sults ineffective. However, not all antipsychotics have 
been studied in double-blind conditions and differenc-
es in efficacy exist between antipsychotics.
Which antipsychotics proved effective in resistant 
OCD in double-blind, placebo-controlled studies?
Efficacy: first generation antipsychotics
Two studies investigated augmentation of SRIs with 
typical antipsychotics (haloperidol and pimozide) 53 54; 
only haloperidol proved to be effective in a double-
blind, placebo-controlled study, particularly in pa-
tients with comorbid tic disorders 54 55. However, the 
side effect profile of haloperidol, with dose-dependent 
extrapyramidal symptoms, limits the potential benefit 
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of this strategy; by comparison, the atypical antip-
sychotics are associated with fewer extrapyramidal 
symptoms, though they are known to be associated 
with a higher risk of metabolic adverse effects 56.
Efficacy: second generation/atypical antipsychotics
Concerning the efficacy of second-generation antip-
sychotic augmentation of SRIs in treatment-resistant 
OCD, there are six RCTs regarding the addition of 
quetiapine 57-61 81, four risperidone  62-65, two aripipra-
zole 66 67, two olanzapine 68 69 and one paliperidone 70. 
Results of double-blind, placebo-controlled studies 
(together with doses used in each study) are sum-
marized in Table II. 
Aripiprazole and risperidone both differentiated from 
placebo in all studies and may be considered effec-
tive. No evidence could be identified for the efficacy 
of adjunctive quetiapine (no difference in response 
between quetiapine and placebo in four of the five 
double-blind studies) and olanzapine (one positive 
study 68 and one negative 69). However, the negative 
study with olanzapine 69 was biased by the fact that 
the Authors included patients not responding to only 
8 weeks of SRI monotherapy; thus patients in both 
the placebo and the olanzapine arms showed a sig-
nificant response rate. Our single-blind study com-
paring olanzapine with risperidone addition showed 
similar response rates to both compounds, suggest-
ing equivalent efficacy  71. We then think that olan-
zapine may be a valid alternative to aripiprazole and 
risperidone as an augmentation strategy in resistant 
patients. The paliperidone negative study 70 suffered 
from the same bias: treatment resistance was defined 
as an entry YBOCS total score of 19 or greater de-
spite at least two adequate SRI monotherapy trials, 
one of which included the SRI currently being taken 
by the patient provided that the duration of treatment 
was only 8 weeks at a medium-to-high dose. Pali-
peridone did not differentiate from placebo: paliperi-
done administration resulted in significant baseline to 
post-treatment reductions in obsessive-compulsive 
symptoms (-7.98 points in YBOCS score), and place-
bo administration also resulted in medium size, trend-
level significant YBOCS changes (-4.02 points). Our 
conclusion is that paliperidone may have a potential 
efficacy in treating OCD patients resistant to SRIs, 
although further studies are needed. Future studies 
might benefit from including patients whose resist-
ance to treatments is prospectively evaluated in a trial 
lasting a minimum of 12 weeks at the maximum dose. 
Comparative effectiveness
Concerning comparative effectiveness of antipsy-
chotics in OCD, we could retrieve only four stud-
ies  71-74. Results of these studies are summarized 
in Table III. The first one compared risperidone and 
haloperidol addition with a crossover design: each 
patient received a 2-week trial of adjunctive risperi-
done, haloperidol and placebo  72; both risperidone 
and haloperidol significantly reduced obsessions 
Table II. Efficacy of antipsychotic augmentation in treatment-resistant OCD: double-blind, placebo-controlled studies.
Antipsychotic Authors Sample (N) Trial duration (weeks) Dose (mg/die) Mean dose (mg/die)
Minimal length of SRI treatment 
before enrollment in the study
Results 
Aripiprazole Muscatello et al., 2011 66
Sayyah et al., 2012 67
40
39
16
12
15 (fixed-dose)
10 (fixed-dose)
15 (fixed-dose)
10 (fixed-dose)
12
12
Aripiprazole > Placebo
Aripiprazole > Placebo
Haloperidol McDougle et al., 1994 54 34 4 2-10 6.2 ± 3.0 12 Haloperidol > Placebo
Olanzapine Bystritsky et al., 2004 68
Shapira et al., 2004 69
26
44
6
6
5-20
5-10
11.2 ± 6.5
6.1 ± 2.1
12
8
Olanzapine > Placebo
Olanzapine = Plabebo
(patients in both arms improved)
Paliperidone Storch et al., 2013 70 34 8 3-9 4.94 8 Paliperidone = Placebo
(patients in both arms improved)
Quetiapine Atmaca et al., 2002 *57
Denys et al., 2004 58
Carey et al., 2005 59
Fineberg et al., 2005 81
Kordon et al., 2008 60
Diniz et al., 2011 #61
27
40
42
21
40
54
8
8
6
16
12
12
50-200
100-300
25-300
50-400
400-600
50-200
91 ± 41
200
168.8 ± 120.8
215 ± 124
-
142 ± 65
12
8
12
12
12
8
Quetiapine > Placebo
Quetiapine > Placebo
Quetiapine = Placebo
Quetiapine = Placebo
Quetiapine = Placebo
Quetiapine < Placebo
Risperidone McDougle et al., 2000 62
Hollander et al., 2003 63
Erzegovesi et al., 2005 64
Simpson et al., 2013 65
36
16
20
60
6
8
6
8
1-6
0.5-3
0.5 (fixed-dose)
0.25-4
2.2 ± 0.7
2.25 ± 0.86
0.5 (fixed-dose)
1.9 ± 1.1
12
12
12
12
Risperidone > Placebo
Risperidone > Placebo
Risperidone > Placebo
Risperidone > Placebo
* Single-blind, placebo-controlled study; # Double-blind placebo and clomipramine controlled study.
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when compared with placebo, and there was a ten-
dency for haloperidol, and to a lesser degree for ris-
peridone, of reducing compulsion and YBOCS total 
score. However, 40% of patients terminated halop-
eridol treatment early owing to intolerable side ef-
fects, versus none in the risperidone phase. Maina 
and colleagues (2008) directly compared, in a single-
blind study, risperidone and olanzapine addition to 
SRIs in resistant OCD patients: the two compounds 
resulted equally effective in improving obsessive-
compulsive symptoms 71. Selvi and coworkers (2011), 
in a single-blind study, compared aripiprazole and 
risperidone augmentation: both drugs proved to be 
effective strategies in resistant patients, although a 
significantly higher response rate was found with ris-
peridone (72.2%) compared to aripiprazole (50%) 73. 
Shoja Shafti and Kaviani (2015), finally, compared in 
a double-blind study the efficacy and safety of ari-
piprazole versus quetiapine. They found a statistical-
ly significant difference in response rates with que-
tiapine (54.5%) compared to aripiprazole (27.3%) 74.
Which antipsychotic dose should be used?
Dose ranges of antipsychotics and mean final doses 
used in double-blind studies on antipsychotic addition 
in resistant OCD are reported in Table  II. Concern-
ing antipsychotics that differentiated from placebo, 
aripiprazole appeared effective at a dose of 10 and 
15 mg/day, olanzapine at a mean dose of 11 mg/day, 
risperidone at a dose comprised between 0.5 and 
2 mg/day. Haloperidol proved effective at a mean final 
dose of 6 mg/day, but with significant side effects. 
How long antipsychotic addition should be maintained? 
Trial duration of double-blind studies on antipsychot-
ic augmentation in treatment-resistant OCD (Tab. II) 
has been comprised between 6 and 12 weeks, with 
the exceptions of 4 weeks in the haloperidol study 54 
and 16 weeks in the aripiprazole one  66. We could 
not find double-blind maintenance studies on antip-
sychotic augmentation in OCD. 
A recent single-blind study compared risperidone to 
CBT augmentation during a six-month maintenance 
phase. Foa and colleagues (2015) followed-up 40 pa-
tients with resistant OCD who responded (Y-BOCS 
decrease ≥ 25%) to 8-week adjunctive risperidone or 
CBT (single-blind, placebo-controlled acute study) 65; 
responders continued the augmentation strategy 
they received acutely over further six months. Re-
sponse was maintained in both groups. Since CBT 
patients improved more during acute treatment than 
risperidone patients, CBT yielded superior outcomes 
six months later  75. Nevertheless, since risperidone 
preserved his efficacy, this study may support the 
need of sustaining antipsychotic augmentation in pa-
tients who acutely responded to this treatment.
However, exactly how long adjunctive antipsychotic 
treatment should be maintained remains an unan-
swered question. Only a study examined relapse rates 
after antipsychotic discontinuation; this study showed 
that the discontinuation of the antipsychotic in patients 
previously responsive only to the augmentation strat-
egy leads to an exacerbation of obsessive-compulsive 
symptoms (relapse) in the vast majority of patients 
(83.3% within the 24-week follow-up); 72.2% of patients 
relapsed within the first 8 weeks from discontinuation 76. 
Although retrospective, this study provides additional 
evidence that antipsychotic augmentation has to be 
maintained for patients who respond to this strategy. 
Discussion and Conclusions
The purpose of this paper was to systematically re-
view available studies on antipsychotic augmentation 
Table III. Comparative efficacy of antipsychotic augmentation in treatment-resistant OCD.
Authors Study design Antipsychotics Sample (N) Trial duration (weeks) Dose (mg/die)
Minimal length of 
SRI treatment before 
enrollment in the study
Results
Li et al., 2005 72 Double-blind Risperidone vs Haloperidol 16 2 Risperidone: 1
Haloperidol: 2
2 Obsessions: Hal = Risp > Placebo
Compulsions: Hal = Risp = Placebo
Total YBOCS: Hal > Risp = Placebo
Maina et al., 2008 71 Single-blind Risperidone vs Olanzapine 50 8 Risperidone: 1-3
Olanzapine: 2.5-10
16 Risperidone = Olanzapine
Selvi et al., 2011 73 Single-blind Risperidone vs Aripiprazole 41 8 Risperidone: 3
Aripiprazole: 15
12 Risperidone > Aripiprazole
Shoja Shafti et al., 2015 74 Double-blind Aripiprazole vs Quetiapine 44 12 Aripiprazole: 10
Quetiapine: 300
12 Quetiapine > Aripiprazole
Hal: Haloperidol; Risp: Risperidone.
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for treatment-resistant OCD, focusing on efficacy and 
comparative effectiveness (where possible) of antip-
sychotics, in order to provide a guidance for clinicians 
on which antipsychotic (and at which dose) should be 
preferred in resistant OCD.
The currently available evidence suggests that antip-
sychotic augmentation of SRIs is an evidence-based 
treatment option for OCD patients not responding to 
at least 12 weeks at a medium-to-high SRI dose. 
Vulink and colleagues examined the efficacy of the 
combination of SRIs and antipsychotic from beginning 
of treatment in non-refractory OCD patients, support-
ing that the combination of quetiapine (300-450 mg) 
and citalopram (60 mg) was more effective than cit-
alopram alone in reducing OCD symptoms in treat-
ment-naive or medication-free OCD patients 77. In our 
opinion, however, given the adverse effect profile of 
long-term antipsychotic use and the lack of additional 
evidence of the efficacy of this combination ab initio, 
antipsychotic augmentation should be reserved for re-
sistant patients. The use of antipsychotics in mono-
therapy either in drug-naïve or resistant patients has 
never been studied under double-blind conditions. 
Clinicians should expect a response rate of approxi-
mately 50% in 4-to-6 weeks after antipsychotic addi-
tion, given that the choice of the right antipsychotic is 
restricted to aripiprazole, risperidone, and olanzapine. 
Our conclusions is supported by two positive double-
blind studies for aripiprazole (none negative), four for 
risperidone (none negative) and one for olanzapine 
(one negative study, but biased – see results). Halop-
eridol addition is also a viable option, particularly in pa-
tients with comorbid tic disorders. Whether resistant pa-
tients with comorbid tic disorders respond better to all 
antipsychotics is still to be determined, as meta-analytic 
studies support this conclusion (patients with tics: NNT 
2.3 vs patients without tics: NNT 5.9) but also say that 
results are biased by the inclusion of the haloperidol 
study results 43. Quetiapine should be regarded as non-
effective in OCD, given results of studies performed to 
date (no difference in response between quetiapine 
and placebo in four of the five double-blind studies).
Data emerging from comparative studies to guide clini-
cians in the choice between aripiprazole, olanzapine and 
risperidone are still preliminary and conclusions can’t be 
drawn; characteristics of patients (e.g. BMI at baseline) 
and side effects generally associated with each different 
antipsychotic may guide the practical choice. 
The characteristic feature of second-generation an-
tipsychotics is a combination of antagonism at the 
dopamine-D2 receptor and at the serotonin-5-HT2a 
receptor. Which receptor-binding, in addition to the 
serotonin reuptake inhibition induced by SSRIs, pri-
marily causes the therapeutic effects of antipsychotic 
augmentation in resistant OCD appears to be un-
clear at the present. Haloperidol and risperidone are 
characterized by a markedly more potent affinity to 
the D2-receptor than quetiapine and olanzapine  78. 
Because haloperidol and risperidone were superior 
to quetiapine and olanzapine in the meta-analytic 
calculations, it may be conjectured that the phar-
macological effects in OCD are primarily caused by 
the D2-receptor blockade of the antipsychotic  47. A 
recent metaregression analysis suggested that dif-
ferences in antipsychotic effectiveness could be due 
to differences in dopamine binding affinities, with in-
creasing D2 and D3 dopamine receptor binding af-
finities associated with greater effectiveness (greater 
YBOCS reduction and higher response rates) 49.
An alternative evidence-based strategy for resistant 
OCD is CBT addition to pharmacotherapy, when CBT 
is available 79. We could find only one acute study which 
directly compared pharmacological (risperidone) and 
psychological (intensive CBT) augmentation in adult 
Table III. Comparative efficacy of antipsychotic augmentation in treatment-resistant OCD.
Authors Study design Antipsychotics Sample (N) Trial duration (weeks) Dose (mg/die)
Minimal length of 
SRI treatment before 
enrollment in the study
Results
Li et al., 2005 72 Double-blind Risperidone vs Haloperidol 16 2 Risperidone: 1
Haloperidol: 2
2 Obsessions: Hal = Risp > Placebo
Compulsions: Hal = Risp = Placebo
Total YBOCS: Hal > Risp = Placebo
Maina et al., 2008 71 Single-blind Risperidone vs Olanzapine 50 8 Risperidone: 1-3
Olanzapine: 2.5-10
16 Risperidone = Olanzapine
Selvi et al., 2011 73 Single-blind Risperidone vs Aripiprazole 41 8 Risperidone: 3
Aripiprazole: 15
12 Risperidone > Aripiprazole
Shoja Shafti et al., 2015 74 Double-blind Aripiprazole vs Quetiapine 44 12 Aripiprazole: 10
Quetiapine: 300
12 Quetiapine > Aripiprazole
Hal: Haloperidol; Risp: Risperidone.
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patients with resistant OCD 65. This comparative study 
suggests that intensive CBT is more effective than ris-
peridone addition to SRIs: response rates were 80% 
and 23% at week  8, respectively; this randomized 
clinical study concluded that patients with OCD re-
ceiving SRIs who continue to have clinically significant 
symptoms should be offered CBT before antipsychot-
ics given its superior efficacy and less negative ad-
verse effect profile, although clinician should remem-
ber that intensive CBT was offered in that study (15 
exposure sessions, daily homework – at least 1 hour 
of self-directed exposures daily, and between-session 
telephone check-ins, at least 2 sessions outside the 
clinic to promote generalization to daily life) 65. Given 
the strength of the evidence for antipsychotic addition, 
we do suggest this option especially in patients who 
showed a partial but unsatisfactory response. 
Further research is still required concerning the op-
timal target dose of antipsychotic to be prescribed in 
resistant patients; the available evidence suggests to 
use the following doses: aripiprazole 10-15 mg/day, 
olanzapine 10  mg/day, risperidone 0.5-2  mg/day. 
Haloperidol proved effective at a mean final dose of 
6 mg/day, but with significant side effects; in clinical 
practice we advise to use it, e.g. when tic disorder 
is comorbid, at lower dosages, and augment up to 
6 mg/day if response is not evident at lower dosages.
Further research is also still required regarding the 
ideal duration of add-on treatment, its long tolerabil-
ity and the evaluation of predictors of response. The 
available evidence points to the need of maintaining 
antipsychotic addition over the long-term in order to 
prevent relapses. On the other hand, however, if such 
treatment is carried out over the long term, patients 
are exposed to the common and serious adverse ef-
fects associated with long-term antipsychotic adminis-
tration, especially metabolic ones: increased glucose, 
triglycerides, abdominal circumference, blood pres-
sure and decreased cholesterol HDL 80. Patients with 
OCD on antipsychotic treatment may be particularly 
at risk for metabolic syndrome and should be care-
fully monitored for metabolic abnormalities and cardio-
vascular complications: a recent study of our research 
group showed that metabolic syndrome was present 
in 21.2% of a sample of 104 OCD patients; metabol-
ic syndrome was associated with the duration of the 
exposure (lifetime) to antipsychotics 56. These results 
add strength to the indication of restricting the use of 
antipsychotic augmentation in resistant patients, when 
CBT is not available or feasible, or is ineffective. We 
strongly advice not using antipsychotic addition to 
SRIs in drug-naïve, never treated patient. 
Further investigations should also assess which 
SRIs are the most suitable for an antipsychotic aug-
mentation strategy. Moreover, additional work is re-
quired to understand the psychobiological mecha-
nisms underlying the efficacy of antipsychotic addi-
tion in resistant OCD.
Take home messages for psychiatric care
•	 Augmentation of SRIs with antipsychotics is an evidence-based strategy in resistant OCD
•	 The overall response rate to antipsychotic addition is around 50%
•	 Among atypical antipsychotics, risperidone and aripiprazole may be considered the most effective in resistant OCD
•	 Further studies are required on the optimal dose and the ideal duration of antipsychotic add-on treatment
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